These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 10417033)
1. Phenytoin and fosphenytoin: a model of cost and clinical outcomes. Armstrong EP; Sauer KA; Downey MJ Pharmacotherapy; 1999 Jul; 19(7):844-53. PubMed ID: 10417033 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department. Rudis MI; Touchette DR; Swadron SP; Chiu AP; Orlinsky M Ann Emerg Med; 2004 Mar; 43(3):386-97. PubMed ID: 14985668 [TBL] [Abstract][Full Text] [Related]
3. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Marchetti A; Magar R; Fischer J; Sloan E; Fischer P Clin Ther; 1996; 18(5):953-66. PubMed ID: 8930434 [TBL] [Abstract][Full Text] [Related]
4. Inappropriate fosphenytoin use in the ED. Johnson J; Wrenn K Am J Emerg Med; 2001 Jul; 19(4):293-4. PubMed ID: 11447516 [TBL] [Abstract][Full Text] [Related]
5. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department. Touchette DR; Rhoney DH Pharmacotherapy; 2000 Aug; 20(8):908-16. PubMed ID: 10939551 [TBL] [Abstract][Full Text] [Related]
10. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370 [TBL] [Abstract][Full Text] [Related]
11. Intramuscular use of fosphenytoin: an overview. Uthman BM; Wilder BJ; Ramsay RE Neurology; 1996 Jun; 46(6 Suppl 1):S24-8. PubMed ID: 8649611 [TBL] [Abstract][Full Text] [Related]
12. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. Coplin WM; Rhoney DH; Rebuck JA; Clements EA; Cochran MS; O'Neil BJ Neurol Res; 2002 Dec; 24(8):842-8. PubMed ID: 12500711 [TBL] [Abstract][Full Text] [Related]
13. Fosphenytoin: worth the cost? Miller MH Ann Emerg Med; 1997 Jun; 29(6):823. PubMed ID: 9174533 [No Abstract] [Full Text] [Related]
14. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. DeToledo JC; Ramsay RE Drug Saf; 2000 Jun; 22(6):459-66. PubMed ID: 10877039 [TBL] [Abstract][Full Text] [Related]
15. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Wilder BJ; Campbell K; Ramsay RE; Garnett WR; Pellock JM; Henkin SA; Kugler AR Arch Neurol; 1996 Aug; 53(8):764-8. PubMed ID: 8759983 [TBL] [Abstract][Full Text] [Related]
16. Fosphenytoin: a novel phenytoin prodrug. Boucher BA Pharmacotherapy; 1996; 16(5):777-91. PubMed ID: 8888074 [TBL] [Abstract][Full Text] [Related]
17. Cost of fosphenytoin. Marble EL Ann Emerg Med; 1998 Jan; 31(1):138-9. PubMed ID: 9437362 [No Abstract] [Full Text] [Related]
18. Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin. DeToledo JC; Lowe MR; Rabinstein A; Villaviza N Epilepsia; 2001 Feb; 42(2):288. PubMed ID: 11240605 [No Abstract] [Full Text] [Related]
19. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy. Knapp LE; Kugler AR J Child Neurol; 1998 Oct; 13 Suppl 1():S15-8; discussion S30-2. PubMed ID: 9796747 [TBL] [Abstract][Full Text] [Related]
20. Pharmacology and pharmacokinetics of fosphenytoin. Browne TR; Kugler AR; Eldon MA Neurology; 1996 Jun; 46(6 Suppl 1):S3-7. PubMed ID: 8649612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]